On November 11, 2015, Immune Pharmaceuticals, Inc. (IMNP) announced financial results for the third quarter of 2015 and provided a business update. This acceptance will enable the company to expand recruitment for the ongoing Phase 2 clinical trial to three planned clinical trial sites in the U.S., including Mount Sinai School of Medicine in New York City.
The biotech giant had other options.
Opko Health (OPK) makes up 1.25% of the SPDR S&P Biotech ETF (XBI). It is a mid-cap stock and has a market cap of ~$6 billion.